Does the media refer more to FTH or QURE?

In the previous week, uniQure had 13 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 19 mentions for uniQure and 6 mentions for Sensei Biotherapeutics. uniQure's average media sentiment score of 0.75 beat Sensei Biotherapeutics' score of 0.63 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive uniQure 7 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FTH or IMNM more profitable?

Immunome's return on equity of -50.56% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -1,012.17% -175.69% Immunome N/A -50.56% -46.93%

Does the media prefer FTH or IMNM?

In the previous week, Immunome had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 8 mentions for Immunome and 6 mentions for Sensei Biotherapeutics. Immunome's average media sentiment score of 1.49 beat Sensei Biotherapeutics' score of 0.63 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Immunome 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FTH or CLDX more profitable?

Celldex Therapeutics' return on equity of -52.35% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -1,012.17% -175.69% Celldex Therapeutics N/A -52.35% -47.61%

Does the media favor FTH or CLDX?

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 6 mentions for Sensei Biotherapeutics and 4 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.69 beat Sensei Biotherapeutics' score of 0.63 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Celldex Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer BEAM or FTH?

In the previous week, Beam Therapeutics had 3 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 9 mentions for Beam Therapeutics and 6 mentions for Sensei Biotherapeutics. Beam Therapeutics' average media sentiment score of 0.99 beat Sensei Biotherapeutics' score of 0.63 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer FTH or NAMS?

In the previous week, Sensei Biotherapeutics had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 6 mentions for Sensei Biotherapeutics and 3 mentions for NewAmsterdam Pharma. Sensei Biotherapeutics' average media sentiment score of 0.63 beat NewAmsterdam Pharma's score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sensei Biotherapeutics (FTH) Competitors

$40.05 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

FTH vs. QURE, IMNM, CLDX, BEAM, and NAMS

Should you buy Sensei Biotherapeutics stock or one of its competitors? Sensei Biotherapeutics's main competitors and comparable companies include uniQure (QURE), Immunome (IMNM), Celldex Therapeutics (CLDX), Beam Therapeutics (BEAM), and NewAmsterdam Pharma (NAMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sensei Biotherapeutics compare to uniQure?

Sensei Biotherapeutics (NASDAQ:FTH) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

In the previous week, uniQure had 13 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 19 mentions for uniQure and 6 mentions for Sensei Biotherapeutics. uniQure's average media sentiment score of 0.75 beat Sensei Biotherapeutics' score of 0.63 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
uniQure	7 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sensei Biotherapeutics has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, uniQure has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sensei Biotherapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
uniQure	$18.67M	165.32	-$198.97M	-$4.01	N/A

Sensei Biotherapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. uniQure's return on equity of -111.96% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
uniQure	-1,350.73%	-111.96%	-29.01%

Sensei Biotherapeutics currently has a consensus price target of $55.00, indicating a potential upside of 37.33%. uniQure has a consensus price target of $65.00, indicating a potential upside of 46.07%. Given uniQure's higher possible upside, analysts clearly believe uniQure is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Summary

uniQure beats Sensei Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Immunome?

Sensei Biotherapeutics (NASDAQ:FTH) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

In the previous week, Immunome had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 8 mentions for Immunome and 6 mentions for Sensei Biotherapeutics. Immunome's average media sentiment score of 1.49 beat Sensei Biotherapeutics' score of 0.63 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Immunome	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sensei Biotherapeutics has a beta of -0.28, indicating that its share price is 128% less volatile than the broader market. Comparatively, Immunome has a beta of 2.13, indicating that its share price is 113% more volatile than the broader market.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sensei Biotherapeutics currently has a consensus price target of $55.00, suggesting a potential upside of 37.33%. Immunome has a consensus price target of $34.64, suggesting a potential upside of 29.43%. Given Sensei Biotherapeutics' higher possible upside, research analysts clearly believe Sensei Biotherapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Immunome's return on equity of -50.56% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
Immunome	N/A	-50.56%	-46.93%

Sensei Biotherapeutics has higher earnings, but lower revenue than Immunome. Immunome is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
Immunome	$6.94M	437.95	-$212.39M	-$2.53	N/A

Summary

Immunome beats Sensei Biotherapeutics on 10 of the 14 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Celldex Therapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Celldex Therapeutics' return on equity of -52.35% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
Celldex Therapeutics	N/A	-52.35%	-47.61%

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 6 mentions for Sensei Biotherapeutics and 4 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.69 beat Sensei Biotherapeutics' score of 0.63 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Celldex Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Sensei Biotherapeutics presently has a consensus price target of $55.00, indicating a potential upside of 37.33%. Celldex Therapeutics has a consensus price target of $56.08, indicating a potential upside of 41.34%. Given Celldex Therapeutics' higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Sensei Biotherapeutics has higher earnings, but lower revenue than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
Celldex Therapeutics	$1.54M	2,023.42	-$258.76M	-$4.35	N/A

Sensei Biotherapeutics has a beta of -0.28, suggesting that its stock price is 128% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

10.5% of Sensei Biotherapeutics shares are held by institutional investors. 7.0% of Sensei Biotherapeutics shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Celldex Therapeutics beats Sensei Biotherapeutics on 7 of the 12 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Sensei Biotherapeutics (NASDAQ:FTH) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Beam Therapeutics has a beta of 2.22, indicating that its stock price is 122% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.28, indicating that its stock price is 128% less volatile than the broader market.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sensei Biotherapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

In the previous week, Beam Therapeutics had 3 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 9 mentions for Beam Therapeutics and 6 mentions for Sensei Biotherapeutics. Beam Therapeutics' average media sentiment score of 0.99 beat Sensei Biotherapeutics' score of 0.63 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Beam Therapeutics presently has a consensus price target of $49.00, suggesting a potential upside of 65.21%. Sensei Biotherapeutics has a consensus price target of $55.00, suggesting a potential upside of 37.33%. Given Beam Therapeutics' higher probable upside, equities analysts plainly believe Beam Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Sensei Biotherapeutics has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.92	-$79.99M	-$0.86	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Summary

Beam Therapeutics beats Sensei Biotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to NewAmsterdam Pharma?

Sensei Biotherapeutics (NASDAQ:FTH) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Sensei Biotherapeutics has a beta of -0.28, meaning that its stock price is 128% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

In the previous week, Sensei Biotherapeutics had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 6 mentions for Sensei Biotherapeutics and 3 mentions for NewAmsterdam Pharma. Sensei Biotherapeutics' average media sentiment score of 0.63 beat NewAmsterdam Pharma's score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sensei Biotherapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

Sensei Biotherapeutics has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
NewAmsterdam Pharma	$22.50M	134.95	-$203.82M	-$2.16	N/A

Sensei Biotherapeutics currently has a consensus target price of $55.00, indicating a potential upside of 37.33%. NewAmsterdam Pharma has a consensus target price of $49.73, indicating a potential upside of 95.78%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

NewAmsterdam Pharma beats Sensei Biotherapeutics on 10 of the 16 factors compared between the two stocks.

Get Sensei Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTH vs. The Competition

Export

Metric	Sensei Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.03B	$4.00B	$7.21B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.13%
P/E Ratio	-0.28	12.71	273.84	25.45
Price / Sales	N/A	1,339.57	624.33	100.83
Price / Cash	N/A	45.00	28.92	35.62
Price / Book	2.72	16.26	10.95	6.39
Net Income	-$21.08M	-$22.85M	$3.49B	$358.69M
7 Day Performance	22.22%	1.41%	1.61%	0.22%
1 Month Performance	64.21%	5.99%	4.41%	-0.10%
1 Year Performance	N/A	49.36%	24.19%	14.04%

Sensei Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTH Sensei Biotherapeutics	4.0909 of 5 stars	$40.05 flat	$55.00 +37.3%	N/A	$1.03B	N/A	N/A	40	Gap Down
QURE uniQure	3.0904 of 5 stars	$47.86 -1.7%	$65.00 +35.8%	+147.9%	$3.38B	$16.10M	N/A	500	Analyst Downgrade
IMNM Immunome	2.868 of 5 stars	$27.07 -1.2%	$34.64 +28.0%	+154.4%	$3.11B	$6.94M	N/A	40	Positive News
CLDX Celldex Therapeutics	2.8132 of 5 stars	$39.24 -1.0%	$56.08 +42.9%	+73.5%	$3.11B	$1.54M	N/A	150	Positive News
BEAM Beam Therapeutics	2.4403 of 5 stars	$29.02 -1.4%	$49.00 +68.8%	+42.0%	$3.04B	$139.74M	N/A	510	Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTH) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensei Biotherapeutics (FTH) Competitors

FTH vs. QURE, IMNM, CLDX, BEAM, and NAMS

How does Sensei Biotherapeutics compare to uniQure?

Summary

How does Sensei Biotherapeutics compare to Immunome?

Summary

How does Sensei Biotherapeutics compare to Celldex Therapeutics?

Summary

How does Sensei Biotherapeutics compare to Beam Therapeutics?

Summary

How does Sensei Biotherapeutics compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensei Biotherapeutics (FTH) Competitors

FTH vs. QURE, IMNM, CLDX, BEAM, and NAMS

How does Sensei Biotherapeutics compare to uniQure?

Does the media refer more to FTH or QURE?

Which has more volatility & risk, FTH or QURE?

Do insiders and institutionals believe in FTH or QURE?

Which has stronger valuation & earnings, FTH or QURE?

Is FTH or QURE more profitable?

Do analysts rate FTH or QURE?

Summary

How does Sensei Biotherapeutics compare to Immunome?

Does the media prefer FTH or IMNM?

Which has more volatility and risk, FTH or IMNM?

Do insiders & institutionals hold more shares of FTH or IMNM?

Do analysts rate FTH or IMNM?

Is FTH or IMNM more profitable?

Which has stronger earnings and valuation, FTH or IMNM?

Summary

How does Sensei Biotherapeutics compare to Celldex Therapeutics?

Is FTH or CLDX more profitable?

Does the media favor FTH or CLDX?

Do analysts rate FTH or CLDX?

Which has stronger valuation and earnings, FTH or CLDX?

Which has more volatility and risk, FTH or CLDX?

Do institutionals & insiders have more ownership in FTH or CLDX?

Summary

How does Sensei Biotherapeutics compare to Beam Therapeutics?

Which has more risk and volatility, BEAM or FTH?

Do insiders and institutionals have more ownership in BEAM or FTH?

Is BEAM or FTH more profitable?

Does the media prefer BEAM or FTH?

Do analysts rate BEAM or FTH?

Which has stronger earnings and valuation, BEAM or FTH?

Summary

How does Sensei Biotherapeutics compare to NewAmsterdam Pharma?

Which has more volatility & risk, FTH or NAMS?

Does the media prefer FTH or NAMS?

Is FTH or NAMS more profitable?

Which has higher valuation & earnings, FTH or NAMS?

Do analysts rate FTH or NAMS?

Do insiders & institutionals believe in FTH or NAMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools